The European HBV Patient Registry –
A TherVacB resource

Markus Cornberg – Hannover Medical School (MHH)

ICE-HBV & LPI Community Webinar 101 on HBV in Europe
24th November 2021
TherVacB: Therapeutic Vaccine to Cure Hepatitis B

**TherVacB:****

- **Aim:** TherVacB vaccine as immunotherapy to cure HBV
- **Evaluation:** in a three-year clinical trial starting in 2022
- **[https://www.thervacb.eu/](https://www.thervacb.eu/)**

**The European HBV Registry:**
- A TherVacB resource rooted in the German Center for Infection Research ‘DZIF’
What is the European HBV Patient Registry?

At the European registry for patients with chronic hepatitis B we perform:

- Recruitment of patients with chronic HBV infection who are eligible and willing to participate in **clinical trials to cure HBV**

- Monitoring of virological and host parameters in patients with chronic HBV infection in advance of any clinical study to **generate knowledge** and **assess potential study participation**

Patient disease registry:
Multicentric, prospective, observational cohort for patients with hepatitis B virus infection
Why is it a good idea to join?

- you will become patient at one of the TherVacB study centers
- TherVacB will perform your routine visits and document your data in the registry
- this helps selecting patients for participation in specific therapies or clinical trials to cure HBV
- through a continuously growing collection of patient data, we will be able to gather valuable information on the natural course of the disease
- every participant supports, with the data generated from him- or herself, to better understanding the HBV-mediated disease and developing or refining therapies to ultimately help the patient community in general
TherVacB has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848223.

Where is the European HBV Patient Registry currently active?

In Italy, Spain, UK and Germany.

- University College London (UCL)
- Royal Free Hospital London (RFH)
- Barts and the London NHS Trust (BLT)
- Hamburg-Eppendorf University Hospital (UKE)
- Hannover Medical School (MHH)
- Leipzig University (ULEI)
- Rechts der Isar Hospital of the Technical University of Munich (MRI)
- Azienda Ospedaliero-Universitaria di Parma (AOP)
- Fundacio Clinic per a la Recerca Biomedica Barcelona (FCRB)
- National Institute for Medical Research Tanzania (TZ)
Who can participate?

You are welcome to join if (inclusion criteria):

• aged >18 years to 70 years, irrespective of gender
• living with confirmed chronic hepatitis B virus infection (HBsAg positive for at least 1 year)
• documented HBeAg status for at least 6 months
• willing to sign informed consent for the cohort (and declared interest on a vaccination trial)
• untreated or treated with NUC

Unfortunately, not if (exclusion criteria):

• co-infected with HIV, HCV (RNA positive)
• living with clinically relevant concomitant liver diseases
• living with significant comorbidities
• receiving immunosuppressive treatment
• living with liver cirrhosis (judged clinically or based on ultrasound/transient elastography)
• history of hepatocellular carcinoma exists
How can I participate?

1. you are a person **living with a chronic HBV infection** and are interested in the TherVacB registry

2. you live close to one of the TherVacB registry centers for your **routine visits**

3. **contact us** online: [https://www.thervacb.eu/patients/patients-contact-us/](https://www.thervacb.eu/patients/patients-contact-us/)

4. you will be **referred to a TherVacB study** center closest to your place of residence

5. a TherVacB study physician will then decide together with you on a possible **inclusion in the registry**, amongst other things based on the set of clinical criteria

All patient data will be safely stored and carefully handled according to consents received, in full compliance with current data protection regulations (GDPR).